What Evestia Clinical does

Evestia Clinical is a global specialist Contract Research Organization (CRO) headquartered in Letchworth Garden City, UK, providing full-service clinical research support to biotechnology and pharmaceutical companies. Originally founded in 1996 as EMAS Pharma, the firm rebranded to Evestia Clinical in March 2025 and is backed by UK private equity firm Kester Capital. The company offers an end-to-end service portfolio spanning project management, site management, regulatory services, clinical monitoring, data management and biostatistics, medical affairs and medical writing, quality assurance, pharmacovigilance, functional service provider (FSP) solutions, and pharmacokinetics expertise. Therapeutic focus is concentrated in five areas — oncology, rare disease, neurology, immunology and inflammation — with cumulative experience across 300+ oncology studies, 120+ rare disease studies, 60+ neurology studies, 50+ cell and gene therapy studies, and a flagship ALS program.

The business operates on a professional services model with project-by-project contracting (Request a Proposal intake), targeting biotech innovators requiring specialized clinical support in complex therapeutic areas. Evestia distributes its services via direct enterprise field sales with a global footprint of 13 offices across the UK, US (Charlottesville, Boston, South San Francisco), Germany, France, Italy, Netherlands, Poland, Spain, Switzerland, and Australia. The technology stack is built on established commercial platforms including Veeva Vault and Zelta for clinical systems, Veeva Vault Safety/Argus/Evigi/PV Works for pharmacovigilance, TrackWise for quality management, and Phoenix WinNonlin/NLME for pharmacokinetic analyses. The platform was materially expanded in 2025–2026 via the merger with Atlantic Research Group (July 2025), which more than doubled headcount and added US presence and late-stage neurology capability, and the acquisition of ICRC-Weyer GmbH (January 2026), which added specialist biostatistics, data management, and medical writing capacity from Berlin.

Name

Evestia Clinical

Legal name

Evestia Clinical Limited

Website

https://evestiaclinical.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

101–250 employees

Short description

Evestia Clinical is a UK-headquartered specialist Contract Research Organization providing full-service clinical trial services to biotech and pharmaceutical companies globally. It focuses on oncology, rare disease, neurology, immunology, and inflammation, operating across 10+ countries with PE backing from Kester Capital.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) / Clinical Research Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

Keywords

• Clinical research services
• Contract research organization
• Clinical trial management
• Pharmacovigilance services
• Biostatistics analysis

Headquarters

HQ city

Stevenage

HQ country

United Kingdom

HQ region

Europe

Offices13 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Services: Evestia Clinical operates as a Contract Research Organization (CRO) providing clinical research services to pharmaceutical and biotech clients. Revenue is generated through service contracts for managing clinical trials, including project management, site management, regulatory services, clinical monitoring, data management, biostatistics, medical affairs, quality assurance, pharmacovigilance, and functional service provider solutions. Services span from Phase I through Phase III and beyond.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Evestia Clinical is a global specialist Contract Research Organization (CRO) providing full-service clinical research capabilities for biotech and pharmaceutical clients. Services span the trial lifecycle from Phase I through Phase III and beyond — including project management, site management, regulatory services, clinical monitoring, data management and biostatistics, medical affairs/medical writing, quality assurance, pharmacovigilance, functional service provider (FSP) solutions, and pharmacokinetics expertise. Therapeutic specialization covers oncology, rare disease, neurology, immunology, and inflammation, augmented by the ICRC-Weyer sub-brand providing biostatistics, data management, and medical writing from Berlin.

Product overview

Evestia Clinical is a global specialist Contract Research Organization (CRO) providing full-service clinical research solutions for biotech innovators. The company operates as a unified platform offering comprehensive services across the clinical trial lifecycle: Project Management, Site Management, Regulatory Services, Clinical Monitoring, Data Management & Biostatistics, Medical Affairs/Medical Writing, Quality Assurance Services, Pharmacovigilance, Functional Service Provider (FSP) solutions, and Pharmacokinetics Expertise. The service offering is organized around five core therapeutic expertise areas: Oncology (63% team expertise, 300+ studies), Rare Disease (50% team expertise, 120+ studies), Neurology (34% team expertise, 60+ studies, since 2004), Immunology (42% team expertise, 60 studies), and Inflammation. The portfolio is augmented by ICRC-Weyer (acquired January 2026), which operates as a sub-brand providing specialist biostatistics, data management, and medical writing capabilities from Berlin. The company utilizes established commercial platforms including Veeva Vault, Zelta, TrackWise, and Phoenix WinNonlin/NLME for service delivery.

Differentiator

Problem solved

Functional benefit

Brands

• ICRC-Weyer: Berlin-based clinical research organization and scientific consultancy providing biostatistics, data management, and medical writing services. Operates under its own brand following acquisition by Evestia Clinical in January 2026.
• Atlantic Research Group (ARG)

Products and services

• Project Management Expert project leadership for seamless clinical trials, providing strategic oversight and coordination across all trial phases for biotech and pharmaceutical clients.
• Site Management Expert management for successful clinical trial sites, ensuring proper site operations and compliance for biotech and pharmaceutical sponsors.
• Regulatory Services Expert regulatory guidance including regulatory strategy, submissions, and compliance support across FDA, EMA, and UK MHRA environments.
• Clinical Monitoring Personalized clinical monitoring oversight from initiation to completion, ensuring trial compliance and data integrity across global sites.
• Data Management & Biostatistics Clinical data management and statistical analysis services providing precise analytical insights across every trial phase, supported by CDISC SDTM/ADaM standards.
• Medical Affairs / Medical Writing Medical affairs and medical writing services guiding clinical development with collaborative support, including scientific writing and regulatory submission preparation.
• Quality Assurance Services Quality assurance services guiding clinical trials with meticulous GCP compliance, audit management, and trial integrity, supported by TrackWise QMS.
• Pharmacovigilance Pharmacovigilance support for therapies including case management, signal detection, and aggregate reporting for clinical and post-marketing projects, using Veeva Vault Safety, Argus, Evigi, and PV Works.
• Functional Service Provider (FSP) Adaptable Functional Service Provider solutions providing flexible team augmentation with specialized expertise in clinical trial functions, supported by Veeva Vault and Zelta platforms.
• Pharmacokinetics Expertise Rigorous PK analyses and models including noncompartmental analysis, population PK, exposure-response analysis, and regulatory submission support using Phoenix WinNonlin and Phoenix NLME.
• ICRC-Weyer (Biostatistics, Data Management, and Medical Writing) Sub-brand offering specialist biostatistics, data management, and medical writing services from Berlin, providing scientific consultancy to biotech and pharmaceutical sponsors.

Quantifiable outcome

• 300+ oncology studies completed
• +4 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability5 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• ICRC-Weyer GmbHcoreStrategic or Co-development Partner · 27 January 2026Berlin-based CRO and scientific consultancy acquired by Evestia Clinical. Founded in 1993 by Prof. Dr. Geerd Weyer, ICRC-Weyer brings specialist capabilities in biostatistics, data management, and medical writing. Managing Director Johann Daniel Weyer joined Evestia Clinical leadership team. ICRC-Weyer continues operating under its brand.
• Atlantic Research Group (ARG)coreStrategic or Co-development Partner · 16 July 2025US-based CRO that merged with Evestia Clinical in July 2025. The merger expands geographical presence in the US and enhances service offerings across multiple therapeutic areas, particularly neurology and late-stage trials. The merger more than doubled the group's size by headcount and capabilities.

Scale indicators14 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Medpace Holdings: US-based mid-tier CRO focused on small and mid-cap biotech and pharma sponsors, with full-service clinical trial delivery across multiple therapeutic areas. Highly comparable to Evestia's positioning as an agile, sponsor-focused specialist alternative to mega-CROs.
• Worldwide Clinical Trials: Mid-tier global CRO with deep specialization in neuroscience, rare disease, and immunology — directly overlapping Evestia's core therapeutic franchises. Comparable as a similarly sized specialist targeting complex trials for biotech sponsors.
• Premier Research: Specialty CRO with strong rare disease, oncology, and pediatric focus serving biotech and mid-size pharma. Closely comparable to Evestia in therapeutic mix, sponsor profile, and mid-tier scale.
• Syneos Health: Large global CRO with a full-service clinical development business and significant biotech sponsor exposure. Comparable as a directly competing mid-to-large CRO serving similar end markets with overlapping therapeutic capabilities.
• Ergomed (acquired by Syneos/Cmed): UK-headquartered specialist CRO historically focused on oncology and rare disease, serving biotech sponsors globally. Highly comparable as a similarly positioned, similarly scaled UK-rooted specialist that Evestia directly competes with.

Broad incumbents

• ICON plc: One of the world's largest CROs offering full-service clinical research across all therapeutic areas, including rare disease and oncology. Comparable as an incumbent that Evestia competes against for biotech and pharma study awards.
• IQVIA: Largest global CRO and life sciences services provider with end-to-end clinical development and real-world evidence capabilities. Comparable as the broad incumbent that defines the scale benchmark for specialist CROs like Evestia.
• Fortrea (formerly Labcorp Drug Development / Covance): Large global CRO spun out of Labcorp, providing full-service clinical trial services across all major therapeutic areas. Comparable as a broad incumbent competitor with overlapping service lines and biotech sponsor coverage.
• Charles River Laboratories: Global CRO and preclinical services provider with growing clinical development footprint, particularly in cell and gene therapy. Comparable as a broad incumbent that overlaps with Evestia in biotech-focused clinical services.

Emerging players

• Clinipace Worldwide: Smaller mid-tier CRO focused on emerging and mid-sized biopharma with adaptive trial design and therapeutic expertise. Comparable as a similarly sized specialist competitor pursuing biotech sponsors with full-service offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/evestia-clinical

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evestia Clinical